Pathstone Family Office’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-7,896
| Closed | -$516K | – | 1499 |
|
|
2022
Q3 | $516K | Buy |
7,896
+3,981
| +102% | +$260K | ﹤0.01% | 1060 |
|
|
2022
Q2 | $238K | Sell |
3,915
-21,550
| -85% | -$1.31M | 0.01% | 881 |
|
|
2022
Q1 | $1.6M | Buy |
25,465
+21,464
| +536% | +$1.35M | 0.04% | 212 |
|
|
2021
Q4 | $303K | Buy |
4,001
+1,976
| +98% | +$150K | 0.01% | 705 |
|
|
2021
Q3 | $226K | Buy |
2,025
+364
| +22% | +$40.6K | 0.01% | 774 |
|
|
2021
Q2 | $269K | Buy |
+1,661
| New | +$269K | 0.01% | 681 |
|